- Specialty drug tier placement varies by plan; the same drug may be Tier 4 on one Connecticut plan and Tier 5 on another, with thousands of dollars in cost-sharing difference.
- Connecticut’s prior-auth reform law requires 72-hour standard / 24-hour urgent responses with automatic approval on missed deadlines.
- Connecticut prohibits copay accumulator adjusters on fully insured commercial plans, allowing manufacturer copay assistance to count toward the patient’s deductible.
- Anthem PPO offers the broadest oncology network including Smilow, MSK, Dana-Farber, and NewYork-Presbyterian; ConnectiCare HMO and UnitedHealthcare EPO are more restricted.
- A private broker pulls the full formulary, verifies the specialty pharmacy network, enrolls the patient in manufacturer copay programs, and monitors quarterly formulary updates.
Connecticut residents managing chronic conditions in 2026 must evaluate four plan attributes before enrolling: (1) specialty-drug formulary tier for the patient’s exact medications, including biosimilars and recently approved therapies; (2) prior authorization and step-therapy requirements that can delay treatment by 4–12 weeks; (3) specialty pharmacy network — Anthem uses Accredo/CarelonRx, ConnectiCare uses CVS Caremark Specialty, UnitedHealthcare uses Optum Specialty Pharmacy; (4) oncology and transplant Centers of Excellence designations that affect both coverage and out-of-pocket cost-sharing. A private broker reads the plan’s full formulary (not the summary), confirms the specialty pharmacy contract, and verifies that the patient’s exact disease specialists are in-network at the right facility tier.
When you manage a chronic condition, health insurance is not an annual administrative task — it is the infrastructure of your medical treatment. A wrong-plan decision in November can mean six months of disease progression in the following calendar year. For Connecticut residents living with multiple sclerosis on Ocrevus infusions ($85,000/year), rheumatoid arthritis on Humira or its biosimilars ($82,000/year list price for branded Humira), Crohn’s disease on Stelara ($98,000/year), type 1 diabetes on insulin pumps and continuous glucose monitors ($14,000–$22,000/year in supplies), cystic fibrosis on Trikafta ($322,000/year), HIV on antiretroviral regimens ($30,000–$48,000/year), or advanced cancer on biologics, targeted therapies, or immunotherapy — the choice of insurance plan in 2026 is the most consequential financial and medical decision you will make all year. This guide is for Connecticut residents who require specialty drugs, oncology care, transplant evaluation, or any complex chronic-disease management — and for the family members who help them choose coverage.
The 2026 Connecticut Chronic-Condition Coverage Landscape
Connecticut’s individual and small-group health insurance market in 2026 is dominated by three carriers — Anthem Blue Cross Blue Shield, ConnectiCare, and UnitedHealthcare — each with substantially different approaches to chronic-condition management. Anthem operates under the BlueCard national network with access to Yale New Haven Health, Hartford HealthCare, Memorial Sloan Kettering (NYC), and NewYork-Presbyterian, making it the most common choice for Connecticut residents with cancer or complex disease requiring tertiary-care referrals. ConnectiCare’s individual HMO has a narrower network focused on Hartford HealthCare and select community hospitals, but it includes Connecticut Children’s Medical Center and has historically offered the most generous specialty drug coverage on the Connecticut individual market. UnitedHealthcare’s Oxford EPO covers Yale New Haven, Hartford HealthCare, and Stamford Health but uses Optum Rx with more aggressive step-therapy protocols.
Sources: Access Health CT 2026 Plans, Yale New Haven Health
The 2026 specialty-drug landscape is shaped by three federal developments. First, the Inflation Reduction Act’s Medicare drug-price negotiation took effect for 10 drugs in January 2026, with negotiated prices applying to Medicare Part D — these prices do not apply to commercial insurance, but they have pulled overall list prices down for some negotiated drugs (Eliquis, Xarelto, Januvia, Jardiance, Imbruvica, Stelara, Enbrel, Farxiga, Entresto, NovoLog/Fiasp). Second, biosimilar adoption accelerated through 2025: Humira biosimilars (Yuflyma, Hyrimoz, Cyltezo) now hold approximately 40% of the U.S. Humira market and are typically placed at Tier 3 (preferred specialty) on Connecticut formularies versus Tier 4 or 5 for branded Humira. Third, the FDA approved several new specialty therapies in 2025 (most notably Casgevy/Lyfgenia for sickle cell disease at $2.2M+ per treatment) that are creating new formulary-management challenges for all carriers.
Sources: CMS Medicare Drug Price Negotiation, FDA Biosimilars
Connecticut’s state-specific protections matter for chronic-condition patients. The Connecticut Insurance Department enforces the federal Mental Health Parity and Addiction Equity Act with annual carrier audits (Bulletin IC-38, 2025). The state’s prior-auth reform law, signed in 2024 and fully effective in 2026, requires carriers to respond to standard prior-auth requests within 72 hours and to urgent requests within 24 hours, with automatic approval if the carrier misses the deadline. The state’s step-therapy override law (CGS 38a-510b) requires carriers to approve an override request within 72 hours when the prescribing physician documents that the step-therapy drug would be harmful, ineffective, or that the patient has already tried it without success. These protections are meaningful but require the patient or broker to know they exist and to invoke them when carriers default to denial.
Sources: CT Insurance Dept
Formulary Tiers and Specialty Drug Coverage
A formulary is the list of prescription drugs that an insurance plan covers, organized into tiers that determine the patient’s cost-sharing. Connecticut commercial plans in 2026 typically use five tiers: Tier 1 (preferred generic, $5–$15 copay), Tier 2 (non-preferred generic and preferred brand, $25–$50 copay), Tier 3 (non-preferred brand, $50–$100 copay), Tier 4 (preferred specialty, $150–$350 copay or 20–30% coinsurance), Tier 5 (non-preferred specialty, $350–$1,200 copay or 30–50% coinsurance). Some plans use a four-tier structure that combines Tiers 4 and 5 into a single specialty tier. The critical observation: a drug’s tier is determined by the plan, not by the manufacturer or the FDA. The same drug (Humira, for example) can be Tier 3 on one Connecticut plan, Tier 4 on another, and excluded entirely from a third. A broker pulls the actual 2026 formulary PDF from each carrier’s producer portal, searches for the patient’s exact NDC code, and verifies the tier placement and quantity limits.
Specialty-drug coinsurance is the silent budget-destroyer for chronic-condition patients. A plan that places Trikafta on Tier 5 at 40% coinsurance with no monthly cap creates a 40% × $322,000/year = $128,800/year out-of-pocket obligation — only capped by the plan’s out-of-pocket maximum ($9,200 individual in 2026). The patient hits the out-of-pocket maximum in January and pays nothing for the rest of the year, but $9,200 in the first month is unaffordable for most households. The fix is structural: choose a plan where Trikafta is placed at Tier 4 with a fixed dollar copay ($350/month, $4,200/year), or choose a plan where the patient can use the manufacturer’s Vertex GPS copay assistance program to cover the entire copay. The broker maps the formulary tier against the manufacturer’s copay program eligibility (most copay programs exclude government-insured patients but cover commercial-plan patients) and identifies the lowest-net-cost option for the year.
Sources: Vertex GPS Patient Support
Formulary changes mid-year are a constant risk. Carriers can remove drugs from the formulary, move drugs to higher tiers, or add new restrictions with 60–90 days notice to the patient under Connecticut Insurance Department regulations. For chronic-condition patients, mid-year formulary changes can require rapid response: filing a formulary exception request, switching to an alternative drug, or appealing the change. A broker monitors the carrier’s formulary updates quarterly (Anthem publishes updates in March, June, September, December) and notifies clients when their medications are affected. This monitoring is part of the broker’s ongoing service after enrollment — not just at the Open Enrollment decision point.
Prior Authorization and Step Therapy: The Hidden Restrictions
Prior authorization (PA) is the carrier’s requirement that the physician obtain plan approval before the drug is dispensed. For specialty drugs, PA is universal — every Tier 4 and Tier 5 drug on every Connecticut commercial plan requires PA. The PA process varies by drug and carrier: some PAs require only the diagnosis code and the physician’s signature (turnaround 24–72 hours); others require extensive clinical documentation, prior treatment history, lab values, and a peer-to-peer call between the prescribing physician and the carrier’s medical director (turnaround 7–21 days). The 2024 Connecticut prior-auth reform law mandated 72-hour standard response and 24-hour urgent response with automatic approval on missed deadlines, but enforcement requires the patient or broker to track the submission date and file a complaint if the deadline is missed.
Sources: AMA Prior Authorization Reform
Step therapy is a related but distinct restriction: the patient must try one or more alternative drugs (typically generics or biosimilars) for a defined period before the plan covers the prescribed drug. For rheumatoid arthritis, a typical step-therapy protocol requires methotrexate for 12 weeks, then a TNF inhibitor (typically a Humira biosimilar) for 12 weeks, before approving Cosentyx or Rinvoq. For multiple sclerosis, the protocol may require interferon beta-1a for 6 months before approving Ocrevus or Kesimpta. For psoriasis, the protocol may require topical therapy and methotrexate before approving Skyrizi or Tremfya. Connecticut’s step-therapy override law (CGS 38a-510b) allows the prescribing physician to request an override when (a) the required step-therapy drug is contraindicated, (b) the drug is expected to be ineffective based on patient characteristics, (c) the patient has tried the drug before without success, or (d) the patient is stable on the requested drug. The override request must be granted within 72 hours; the broker assists the patient in filing the override and tracking the response.
Quantity limits are the third hidden restriction. A plan may approve Humira but limit dispensing to one pen every 14 days, even when the prescribed regimen is every 7 days for severe disease. Quantity-limit overrides follow a similar process to step-therapy overrides: the physician documents medical necessity for the higher quantity, and the carrier must respond within 72 hours under Connecticut regulations. The broker reads the formulary’s quantity-limit notations (typically denoted ‘QL’ next to the drug name) before enrollment and identifies any plan that imposes quantity limits below the patient’s prescribed regimen.
Oncology Networks: Smilow, Hartford, Memorial Sloan Kettering
Cancer treatment is among the most network-sensitive medical needs because the difference between a community oncology practice and a National Cancer Institute (NCI)-designated comprehensive cancer center can affect both treatment options and outcomes. Connecticut has two NCI-designated comprehensive cancer centers: Smilow Cancer Hospital at Yale New Haven (NCI-designated since 1974) and the Carole and Ray Neag Comprehensive Cancer Center at UConn Health (NCI-designated since 2014). Hartford HealthCare Cancer Institute and Stamford Hospital’s Bennett Cancer Center are not NCI-designated but maintain active clinical trial programs and strong oncology teams. For complex or rare cancers, many Connecticut patients seek care at Memorial Sloan Kettering Cancer Center (NYC), Dana-Farber Cancer Institute (Boston), or NewYork-Presbyterian/Columbia. The broker verifies in-network status at the patient’s preferred facility and at the alternative tertiary-care facilities before enrollment.
Sources: Smilow Cancer Hospital, Memorial Sloan Kettering, NCI Designated Centers
Network status varies by carrier and plan in 2026. Anthem’s PPO includes Smilow, UConn’s Neag, Hartford HealthCare Cancer Institute, Stamford Hospital Bennett, Memorial Sloan Kettering (NYC), Dana-Farber (Boston), and NewYork-Presbyterian/Columbia — the broadest oncology coverage in the Connecticut market. ConnectiCare’s HMO includes Hartford HealthCare, Smilow (with PCP referral), and Stamford Hospital but requires prior authorization for out-of-state treatment. UnitedHealthcare’s Oxford EPO includes Smilow, Hartford HealthCare Cancer Institute, and Stamford Hospital but excludes Memorial Sloan Kettering as in-network (covered only for emergencies). For Connecticut residents with breast cancer, lung cancer, colorectal cancer, or prostate cancer (the four most common cancers in the state), Anthem PPO is typically the optimal choice. For rare cancers requiring specialized centers in Boston or New York, Anthem PPO is essentially the only option among Connecticut marketplace plans.
Oncology drug coverage requires separate analysis from the broader formulary. Cancer-specific specialty drugs — biologics like Keytruda ($165,000/year), Opdivo ($150,000/year), Tagrisso ($175,000/year), Verzenio ($175,000/year), and CAR-T therapies like Yescarta or Kymriah ($475,000–$525,000 per treatment) — are often handled under medical benefits (not pharmacy benefits) when infused in a clinic setting. This shifts the cost-sharing from pharmacy copay to medical coinsurance, which is typically 20–30% on Gold plans and 30–40% on Silver plans. The broker confirms the billing path (medical vs pharmacy) for each oncology drug and models the patient’s expected out-of-pocket cost under each plan, including manufacturer copay assistance and patient foundation grants (CancerCare Co-Payment Assistance Foundation, PAN Foundation, Patient Advocate Foundation Co-Pay Relief).
Transplant Coverage and Centers of Excellence
Organ transplant coverage requires a separate plan-design analysis because most commercial plans use ‘Center of Excellence’ (COE) networks for transplants — a tighter sub-network than the main provider network. Yale New Haven Transplant Center is one of the largest transplant programs in New England, performing kidney, liver, pancreas, and heart transplants. Hartford Hospital performs kidney transplants and is part of the Hartford HealthCare transplant program. Connecticut Children’s performs pediatric kidney transplants. For lung transplants, bone marrow transplants, and many pediatric transplants, Connecticut residents typically travel to Boston (Mass General, Brigham and Women’s, Boston Children’s), NYC (NewYork-Presbyterian/Columbia, Mount Sinai, NYU), or Cleveland Clinic.
Sources: Yale New Haven Transplant Center, UNOS Transplant Centers
Anthem’s PPO includes its Blue Distinction Centers+ for Transplants program — a national network of high-volume, high-outcome transplant centers including Yale New Haven, Mass General, Brigham and Women’s, NewYork-Presbyterian/Columbia, and Cleveland Clinic. UnitedHealthcare uses its UnitedHealthcare Transplant Solutions COE network with similar coverage. ConnectiCare’s transplant network is narrower, focused on Yale New Haven and Hartford Hospital with case-by-case authorization for out-of-state COEs. The COE designation typically means lower cost-sharing for in-network transplants (often $0 deductible and $0 coinsurance at COE facilities) and travel/lodging reimbursement for the patient and one caregiver during the evaluation, surgery, and follow-up period. For Connecticut patients needing a transplant outside Connecticut, the broker verifies COE coverage and pre-authorization requirements before enrollment.
Specialty Pharmacy: Accredo, CVS Specialty, Optum
Specialty pharmacies dispense the high-cost, often-injectable medications that treat chronic conditions. Most commercial plans require specialty drugs to be filled through a specific specialty pharmacy network rather than a retail pharmacy. Anthem’s Connecticut plans use CarelonRx Specialty Pharmacy (formerly IngenioRx) as the preferred specialty pharmacy, with Accredo (Express Scripts) as an alternative for specific drug classes. ConnectiCare uses CVS Caremark Specialty Pharmacy. UnitedHealthcare uses Optum Specialty Pharmacy (formerly BriovaRx). For patients on specialty drugs, the choice of plan effectively chooses the specialty pharmacy — the patient cannot switch pharmacies without changing carriers.
Sources: CarelonRx, Accredo, CVS Specialty, Optum Specialty
Specialty pharmacy service models matter for chronic-condition patients. The leading specialty pharmacies all provide refrigerated shipping (overnight, signature required) for biologics and gene therapies, dedicated clinical pharmacists for medication counseling, refill reminders, and side-effect management calls. Service quality varies: Accredo has historically scored highest in patient satisfaction surveys for autoimmune and oncology medications; CVS Specialty leads in HIV and transplant immunosuppression; Optum Specialty leads in oncology infusion coordination. For patients with complex polypharmacy (multiple specialty drugs from multiple manufacturers), some specialty pharmacies offer ‘med synchronization’ programs that align refill dates across all medications. The broker discusses these service-quality dimensions with the patient and weighs them against premium and formulary considerations.
Manufacturer Copay Cards and Accumulator Adjusters
Pharmaceutical manufacturers offer copay assistance programs (often called ‘copay cards’ or ‘savings programs’) that pay the patient’s out-of-pocket cost for specialty drugs, often reducing the patient’s monthly out-of-pocket cost to $0–$25. The manufacturer pays the difference between the plan’s copay/coinsurance and the patient’s nominal contribution. Examples: Humira Complete Savings Card (reduces patient copay to $5/month, up to $14,000/year of assistance), Stelara withMe Patient Support (similar structure), Trikafta via Vertex GPS Patient Support (covers patient’s out-of-pocket portion for eligible commercial-plan patients), Ocrevus Co-Pay Program ($0 patient copay for eligible commercial-plan patients).
Sources: Humira Complete
Copay accumulator adjusters and copay maximizers are insurer programs that prevent manufacturer copay assistance from counting toward the patient’s deductible or out-of-pocket maximum. Under a traditional copay arrangement, if the manufacturer pays $4,000 toward the patient’s $4,500 specialty drug copay in January, the patient’s deductible and out-of-pocket maximum credit the full $4,500 — the patient reaches the out-of-pocket maximum quickly and has minimal remaining cost-sharing for the year. Under a copay accumulator, only the patient’s $500 out-of-pocket contribution counts toward the deductible — the patient’s deductible is not reduced by the $4,000 manufacturer payment. This significantly increases the patient’s annual out-of-pocket cost. As of 2026, Connecticut’s House Bill 6710 (signed 2023, effective 2024) prohibits copay accumulator adjusters on most commercial plans sold in the state, requiring manufacturer copay assistance to count toward the patient’s cost-sharing obligation. This Connecticut protection does not extend to self-funded ERISA plans, which many large Connecticut employers use.
Sources: All Copays Count Coalition
Four Real CT Chronic-Condition Scenarios
Scenario 1: The New Haven MS Patient on Ocrevus
A 38-year-old graphic designer in New Haven was diagnosed with relapsing-remitting multiple sclerosis in 2024. Her neurologist at Yale New Haven Multiple Sclerosis Center prescribed Ocrevus (ocrelizumab), administered as a twice-yearly IV infusion at the Smilow infusion center. The drug’s list price is approximately $85,000/year. She was on her employer’s UnitedHealthcare Oxford EPO plan in 2025 but accepted a freelance contract for 2026 that ended her group coverage effective December 31, 2025. Her 2026 projected income was approximately $78,000 (380% FPL for a household of one).
The broker pulled the 2026 formularies for Anthem Gold PPO, ConnectiCare Gold HMO, and UnitedHealthcare Oxford Gold EPO. Anthem placed Ocrevus on Tier 4 specialty at 30% coinsurance under medical benefits (infused at in-network facility) with no step therapy required. ConnectiCare placed Ocrevus on Tier 4 at 25% coinsurance but required step therapy through Plegridy first (which the patient had not tried). UnitedHealthcare placed Ocrevus on Tier 4 at 30% coinsurance with prior authorization but no step therapy. The broker recommended the Anthem Gold PPO ($580/month after APTC of $260/month) because Smilow infusion center was in-network at the highest network tier (Yale New Haven Health ‘Tier 1’ designation), avoiding additional facility-fee cost-sharing that ConnectiCare would impose. The broker also enrolled the patient in the Ocrevus Co-Pay Program, which covered the patient’s coinsurance up to $20,000/year — reducing the patient’s out-of-pocket Ocrevus cost to $0. Total annual coverage cost: $6,960 in premiums; total Ocrevus cost: $0.
Scenario 2: The Hartford Crohn’s Disease Patient on Stelara
A 29-year-old teacher in Hartford was diagnosed with Crohn’s disease in 2022 and had been on Stelara (ustekinumab) infusions every 8 weeks since 2023, with excellent disease control. The drug’s list price is approximately $98,000/year. Her employer’s plan (a self-funded ERISA plan administered by Cigna) had used a copay accumulator adjuster, which had cost her approximately $4,200 in extra out-of-pocket cost during 2025. She lost the employer coverage in February 2026 when she switched school districts and had a 30-day waiting period before the new employer plan started.
The broker analyzed the 30-day gap and the 2026 marketplace options. Stelara was on the federal IRA negotiation list, with a Medicare-negotiated price effective January 2026 that pulled commercial list prices down slightly. The new school district’s employer plan was an Anthem PPO without a copay accumulator (Connecticut’s accumulator-prohibition law applied because it was fully insured, not self-funded). The broker recommended a 30-day STLDI plan from Pivot Health ($165 for the month) as the bridge, because the patient had no infusions scheduled during the gap and the STLDI provided basic emergency-only coverage at a small premium. When the new employer Anthem PPO started March 1, the broker confirmed Stelara was on Tier 4 specialty at $250/month fixed copay (not coinsurance), with infusions covered at Hartford Hospital Crohn’s & Colitis Center in-network. The Stelara withMe copay assistance program covered the $250/month, reducing the patient’s out-of-pocket Stelara cost to $0/year versus the $4,200 the prior accumulator had cost.
Scenario 3: The Stamford Breast Cancer Patient (Newly Diagnosed)
A 47-year-old marketing executive in Stamford was diagnosed with HER2-positive breast cancer in October 2025. Her treatment plan included neoadjuvant chemotherapy with TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) starting January 2026, followed by surgery in May 2026 and a year of trastuzumab + pertuzumab maintenance through May 2027. Her oncologist was at Memorial Sloan Kettering’s Westchester satellite (15 minutes from Stamford) with surgery planned at MSK’s Manhattan main campus. She was on her employer’s Anthem PPO in 2025 but the employer was switching to UnitedHealthcare Oxford EPO effective January 2026.
The broker identified the critical problem: UnitedHealthcare Oxford EPO did not include Memorial Sloan Kettering as in-network. Continuing care at MSK on the new plan would generate $400,000–$600,000 in out-of-network claims with the patient paying 40% coinsurance after a $25,000 out-of-network deductible. The broker recommended the patient decline the employer’s new UnitedHealthcare plan and enroll in an off-marketplace Anthem PPO Gold plan ($1,420/month for individual coverage, with the patient’s pre-tax salary contribution producing a net cost similar to the employer premium). The Anthem PPO included MSK Westchester and MSK Manhattan as in-network at preferred-provider tier. The broker also coordinated with the patient’s HR to obtain the employer’s monthly health insurance allowance as taxable cash compensation (some Connecticut employers permit this when the employee opts out of group coverage). Total impact: avoiding $200,000+ in out-of-network exposure and maintaining continuity at MSK throughout 18 months of active treatment.
Scenario 4: The Greenwich Cystic Fibrosis Family on Trikafta
A 9-year-old child in Greenwich with cystic fibrosis was prescribed Trikafta (elexacaftor/tezacaftor/ivacaftor) by her pulmonologist at Yale New Haven Cystic Fibrosis Center. The drug’s list price is approximately $322,000/year. The family had been on an Anthem PPO Platinum plan through the father’s employer in Manhattan, with Trikafta on Tier 4 at $50/month copay through Vertex GPS Patient Support. The father changed jobs to a Stamford-based firm in January 2026 whose group plan was ConnectiCare HMO.
The broker pulled the ConnectiCare HMO formulary: Trikafta was listed but required prior authorization with documentation of CF diagnosis confirmed by genetic testing for eligible CFTR mutations (the child’s F508del/F508del genotype qualified), prescribed by a pulmonologist at a CF Foundation–accredited center (Yale qualified), and step therapy through prior CFTR modulator (the child had been on Trikafta directly without prior CFTR modulator therapy). The broker recommended the family decline the employer’s ConnectiCare plan and enroll in an off-marketplace Anthem PPO Gold family plan ($2,640/month for family of four). Anthem placed Trikafta on Tier 4 with no step therapy and approved the prior auth within 48 hours of submission. Vertex GPS Patient Support covered the patient’s monthly copay, maintaining $0 out-of-pocket for Trikafta. The broker also identified that the employer offered a Section 125 cafeteria plan option allowing the father to pay the Anthem premium with pre-tax dollars, reducing the effective premium by approximately 32% for a household in the 24% federal and 6.99% state brackets.
Why a Private Broker Matters for Chronic Conditions
For Connecticut residents managing chronic conditions, a private broker delivers value that no online comparison tool or carrier-direct sales channel can match. The broker performs five tasks before enrollment that are otherwise the patient’s responsibility: (1) pulls the full 2026 formulary PDF from each carrier’s producer portal and confirms tier placement, quantity limits, and prior-auth requirements for every medication the patient takes; (2) verifies in-network status at the patient’s preferred treatment facilities, including any Centers of Excellence designations for oncology, transplant, or specialty surgery; (3) confirms the specialty pharmacy network and any service-model differences (clinical pharmacist support, refill synchronization, refrigerated shipping); (4) enrolls the patient in manufacturer copay assistance programs and confirms the Connecticut copay-accumulator prohibition applies; (5) coordinates with the patient’s specialists for prior-auth submissions and tracks responses against Connecticut’s 72-hour standard / 24-hour urgent deadlines. After enrollment, the broker monitors quarterly formulary updates and notifies the patient of changes that affect their medications. The broker’s compensation is paid by the insurance carrier — the patient pays nothing for this expert guidance.
Get Expert Help Choosing Coverage for Your Condition
Managing a chronic condition requires a plan that covers your exact medications, your exact specialists, and your exact treatment facilities. A private broker reads the formulary and the network before you enroll. Schedule a confidential consultation today.